Skip to content
ppharmaranks
Menu
Class IICompleted

Phenazopyridine HCl Tablets USP recall

FDA recall D-0545-2024 · initiated May 28, 2024

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jun 19, 2024How we research

Winder Laboratories, LLC recalled Phenazopyridine HCl Tablets USP in May 2024 — an FDA Class II recall (D-0545-2024) because Product Mix Up. A bottle of Phenazopyridine HCl tablets USP 100 mg contained Phenobarbital tablets 16.2 mg.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Product Mix Up. A bottle of Phenazopyridine HCl tablets USP 100 mg contained Phenobarbital tablets 16.2 mg.

Labelling, packaging or a product mix-up

The wrong information — or the wrong medicine — ended up in the pack. A mix-up is a manufacturing failure that can still be dangerous to swallow.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot#: 1142404 Exp. Date 02/27/2027

Quantity recalled: 473 cases (5676 Bottles)

Details

Product
Phenazopyridine HCl Tablets USP, 100 mg, 100-count bottles, Rx Only, Manufactured by: Winder Laboratories, LLC. 716 Patrick Industrial Lane, Winder, GA 30680, NDC 75826-114-10,
Recalling company
Winder Labs LLC
Classification
Class II
Status
Completed
Type
Voluntary: Firm initiated
Distribution
Nationwide within the United States
Initiated
May 28, 2024
FDA report date
Jun 19, 2024
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Phenazopyridine HCl Tablets USP recalled?
Winder Laboratories, LLC recalled Phenazopyridine HCl Tablets USP in May 2024 — an FDA Class II recall (D-0545-2024) because Product Mix Up. A bottle of Phenazopyridine HCl tablets USP 100 mg contained Phenobarbital tablets 16.2 mg. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Phenazopyridine HCl Tablets USP recalled?
Per the FDA enforcement record, the reason for recall D-0545-2024 was: Product Mix Up. A bottle of Phenazopyridine HCl tablets USP 100 mg contained Phenobarbital tablets 16.2 mg.
Is a recalled Phenazopyridine HCl Tablets USP dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Phenazopyridine HCl Tablets USP are affected?
Distributed: Nationwide within the United States. The recall covers these lots — Lot#: 1142404 Exp. Date 02/27/2027. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0545-2024.

Source: openFDA Drug Enforcement record D-0545-2024

← All drug recalls